This content originates from Baxter International Inc. prior to the company establishing its chronic kidney care and acute therapies businesses into one standalone company, Vantive. This content might contain references to products/brands/persons/services that are not applicable or relevant at the present time. Please contact us in case of any questions.
Baxter Supports add-on payment in proposed ESRD payment rule to spur innovation for dialysis patients
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today issued this statement:
We support the add-on payment that is included in the End-Stage Renal Disease (ESRD) Prospective Payment System proposed rule released by the Centers for Medicare & Medicaid Services. The proposed rule is a significant shift from the current system and will have a positive impact on patient care. We believe it would increase patient access to innovative devices and technology that improve outcomes for those living with kidney disease. We look forward to working with the community and the Administration to ensure that patients will have access to new and innovative treatments.
With this rule and the Advancing American Kidney Health Initiative, the Administration is putting once-in-a-generation policies in place to improve the lives of those with kidney disease,” said Laura Angelini, general manager of Baxter’s Renal Care business. “Building on our 65-year legacy in kidney disease, we will continue to advance innovation across dialysis modalities that reduces complications, improves outcomes and makes dialysis care more efficient.
Laura Angelini
General manager of Baxter’s Renal Care business
About ESRD in the U.S.
- Chronic kidney disease impacts the lives of more than 30 million Americans. Of those, more than 726,000 have ESRD, or kidney failure, and require dialysis treatment or an organ transplant to survive.1
- Medicare provides coverage for ESRD patients, regardless of age. According to USRDS, Medicare spends more than $114 billion on patients with chronic kidney disease annually, which includes $35 billion on ESRD patients.
- Currently all renal dialysis services are bundled into the single per treatment payment paid to ESRD facilities as a “bundle” under the ESRD prospective payment system (PPS). Although the bundled payment base rate is updated each year based on inflation and productivity, it has not adequately accounted for the costs of new technologies.
About Vantive
Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility, efficiency and therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.
References
-
USRDS ADR 2018:Vol 2 ESRD, Chap 1, Table 1.4.